Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug duo aims to improve blood cancer treatment

NCT ID NCT05636514

First seen Jan 05, 2026 · Last updated Apr 29, 2026 · Updated 15 times

Summary

This early-phase study tests whether adding an experimental drug (defactinib) to an approved oral treatment (decitabine/cedazuridine) is safe and can work better for people with certain blood cancers like MDS, AML, and CMML. About 12 adults will take the approved drug alone for the first month, then both drugs together for five days each month. The main goal is to find the safest dose and watch for side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • Concord Repatriation and General Hospital

    RECRUITING

    Sydney, New South Wales, 2139, Australia

    Contact

  • Nepean Hospital

    RECRUITING

    Sydney, New South Wales, 2747, Australia

    Contact

  • Prince of Wales Hospital

    RECRUITING

    Sydney, New South Wales, 2031, Australia

    Contact

  • Royal Prince Alfred Hospital

    RECRUITING

    Sydney, New South Wales, 2050, Australia

    Contact

  • Westmead Hospital

    RECRUITING

    Westmead, New South Wales, 2145, Australia

    Contact

Conditions

Explore the condition pages connected to this study.